Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Núria Porta et al.|Cancer Discovery|2021Cited by 161
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Sarah Ward et al.|Cancer Discovery|2020Cited by 134
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemini Sumanasuriya, Johann S. de Bono, George Seed et al.|European Urology|2021Cited by 65
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean C. Tien, Arul M. Chinnaiyan, Jie Luo et al.|Cell Reports Medicine|2024Cited by 28
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean C. Tien, Arul M. Chinnaiyan, Yu Chang et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1